US 12,409,139 B2
Stable parenteral formulations of duloxetine
Chandrashekhar Kocherlakota, Tarbund Secunderabad (IN); Nagaraju Banda, Kukatpally Hyderabad (IN); Santhosh Kumar Mankala, Old Bowenpally Hyderabad (IN); Suresh Pachaiyappan, Thiruvanmiyur Chennai (IN); and Anji Reddy Keshireddy, Gajularamaram Hyderabad (IN)
Assigned to LEIUTIS PHARMACEUTICALS LLP, Balanagar (IN)
Filed by LEIUTIS PHARMACEUTICALS LLP, Balanagar Hyderabad (IN)
Filed on Nov. 3, 2023, as Appl. No. 18/386,863.
Application 18/386,863 is a continuation of application No. 17/778,906, abandoned, previously published as PCT/IB2020/061263, filed on Nov. 30, 2020.
Prior Publication US 2024/0058272 A1, Feb. 22, 2024
Int. Cl. A61K 9/19 (2006.01); A61K 9/00 (2006.01); A61K 31/381 (2006.01)
CPC A61K 9/19 (2013.01) [A61K 9/0019 (2013.01); A61K 31/381 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A lyophilized parenteral formulation consisting essentially of duloxetine hydrochloride, and one or more pharmaceutically acceptable excipients,
wherein a content of Duloxetine Alcohol, Duloxetine Napthol 4-yl isomer, Alpha Napthol and Duloxetine Beta napthol-1-yl isomer individually is less than 0.5% w/w.